Phio Pharmaceuticals (PHIO) Q4 2025 earnings summary

Executive summary

• Completed treatment phase for PH-762 Phase 1b dose escalation trial with favorable safety, tolerability, and pathology data.

• Advanced CMC and toxicology initiatives for PH-762, supporting future pivotal clinical development.

• Presented new PH-762 data at major scientific conferences and prepared for FDA submission in Q2 2026.

Financial highlights

• Cash and cash equivalents were $21.0 million at December 31, 2025, up from $5.4 million at December 31, 2024.

• Net loss for 2025 was $8.7 million, or ($1.45) per share, compared to $7.2 million, or ($9.08) per share, in 2024.

• Research and development expenses increased 27% year-over-year, driven by PH-762 program advancement and higher compensation.

• General and administrative expenses rose 23% year-over-year due to higher professional services and stock-based compensation.

• Multiple financings and warrant exercises in 2025 generated $23.7 million in net proceeds, extending cash runway into H1 2027.

Outlook and guidance

• FDA submission for PH-762 next clinical study design targeted for Q2 2026.

• Cash runway expected to extend into the first half of 2027, supporting ongoing clinical and operational activities.